Teclistamab Clinical Trials
22 recruitingDrug
Phase 211Phase 34Phase 13Phase 42
Showing 1–20 of 22 trials
Recruiting
Phase 2
Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)
Multiple Myeloma
Noffar Bar50 enrolled2 locationsNCT06993675
Recruiting
Phase 2
A Phase II Trial of Teclistamab in Participants With Previously Treated Immunoglobulin Light-chain (AL) Amyloidosis
AL Amyloidosis
European Myeloma Network B.V.30 enrolled10 locationsNCT06649695
Recruiting
Phase 2
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
Multiple Myeloma
SCRI Development Innovations, LLC100 enrolled17 locationsNCT05972135
Recruiting
Phase 2
Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab.
Multiple Myeloma (MM)
European Myeloma Network B.V.150 enrolled29 locationsNCT07107529
Recruiting
Phase 4
A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and Refractory Multiple Myeloma
Multiple Myeloma
Johnson & Johnson Private Limited75 enrolled12 locationsNCT07030517
Recruiting
Phase 3
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
Janssen Research & Development, LLC400 enrolled39 locationsNCT07258511
Recruiting
Phase 1
Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma
Refractory Multiple MyelomaRecurrent Multiple Myeloma
National Cancer Institute (NCI)26 enrolled14 locationsNCT06465316
Recruiting
A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials
Janssen-Cilag Ltd.900 enrolled68 locationsNCT06285318
Recruiting
Phase 3
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Multiple Myeloma
Janssen Research & Development, LLC1,590 enrolled263 locationsNCT05552222
Recruiting
Phase 3
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Multiple Myeloma
European Myeloma Network B.V.1,594 enrolled211 locationsNCT05243797
Recruiting
Phase 3
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
Multiple Myeloma
Janssen Research & Development, LLC795 enrolled242 locationsNCT06208150
Recruiting
Phase 2
Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study)
Multiple Myeloma
Carl Ola Landgren, MD, PhD50 enrolled1 locationNCT06100237
Recruiting
Phase 1
A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma
Multiple Myeloma
Memorial Sloan Kettering Cancer Center18 enrolled7 locationsNCT07105059
Recruiting
Phase 1Phase 2
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
Acute Myeloid LeukemiaHaematological Malignancy
CellCentric Ltd.250 enrolled39 locationsNCT04068597
Recruiting
Phase 4
Plan Development for Giving Teclistamab in the Outpatient Setting
Multiple MyelomaRefractory CancerRelapsed Cancer
University Health Network, Toronto15 enrolled1 locationNCT06251076
Recruiting
Phase 2
Teclistamab-Daratumumab in AL Amyloidosis
Amyloid Light-chain Amyloidosis
Suzanne Lentzsch, MD25 enrolled1 locationNCT07110844
Recruiting
Phase 2
Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma
Multiple Myeloma
University Hospital, Lille74 enrolled29 locationsNCT05572229
Recruiting
Phase 2
MMRC Horizon One Adaptive Platform Trial Evaluating Therapies in RRMM
Refractory Multiple MyelomaRelapse Multiple Myeloma
Multiple Myeloma Research Consortium300 enrolled13 locationsNCT06171685
Recruiting
Phase 2
Immuno-PRISM (PRecision Intervention Smoldering Myeloma)
Irene Ghobrial, MD52 enrolled3 locationsNCT05469893
Recruiting
Study on the Clinical Efficacy of Teclistamab
Multiple MyelomaHematologic Diseases
Universitaire Ziekenhuizen KU Leuven100 enrolled17 locationsNCT06477783